Jaguar Health (DB:1JA) - Aandelenkoers, Nieuws & Analyse

1JA Overzicht aandelen

A commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. Meer informatie

1JA fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 41.8% per jaar groeien

De winst is de afgelopen 5 jaar met 0.7% per jaar gegroeid

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Jaguar Health, Inc. Concurrenten

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€57.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Jaguar Health
Historische aandelenkoersen
Huidige aandelenkoers	US$7.56
52 Week Hoogtepunt	US$36.00
52 Week Laag	US$2.55
Bèta	0.88
11 maand verandering	0%
3 maanden verandering	-4.98%
1 Jaar Verandering	-69.86%
33 jaar verandering	-99.94%
5 jaar verandering	-99.94%
Verandering sinds IPO	-99.99%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	1JA	DE Pharmaceuticals	DE Markt
7D	0%	-0.3%	0.8%
1Y	-69.9%	-18.3%	8.6%

Rendement versus industrie: 1JA presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -18.3 % opleverde.

Rendement versus markt: 1JA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is 1JA's price volatile compared to industry and market?
1JA volatility
1JA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 1JA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 1JA in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	49	Lisa Conte	jaguar.health

Jaguar Health, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Jaguar Health zich tot de beurswaarde?
1JA fundamentele statistieken
Marktkapitalisatie	€10.65m
Inkomsten(TTM)	-€32.36m
Inkomsten(TTM)	€9.24m

1.2x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is 1JA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
1JA resultatenrekening (TTM)
Inkomsten	US$10.19m
Kosten van inkomsten	US$2.06m
Brutowinst	US$8.13m
Overige uitgaven	US$43.79m
Inkomsten	-US$35.67m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.86
Brutomarge	79.79%
Nettowinstmarge	-350.18%
Schuld/Eigen Vermogen Verhouding	172.7%

Hoe presteerde 1JA op de lange termijn?

Bekijk historische prestaties en vergelijking

1JA Overzicht aandelen

Beloningen

Risicoanalyse

Jaguar Health, Inc. Concurrenten

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

XTRA:HIGH

€57.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Recent updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health, Inc.'s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34